SCHEMBL711055

SCHEMBL711055

ClCc1ccc(-n2cccn2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.63
DRD2 P14416 1/20 0.55
DRD4 P21917 1/20 0.55
DRD3 P35462 1/20 0.55
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 1/20 0.53
MAPK1 P28482 1/20 0.53
CHRM1 P11229 3/20 0.51
CHRNA7 P36544 1/20 0.45
CHRNA10 Q9GZZ6 1/20 0.45
CHRNA9 Q9UGM1 1/20 0.45
MPO P05164 1/20 0.43
BRS3 P32247 1/20 0.42
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
PKM P14618 1/20 0.41
HCRTR1 O43613 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341894 0.83 NOTUM (0.78) NOTUMDRD2DRD4DRD3KDM4E
SCHEMBL28181607 0.81 NOTUM (0.59) NOTUMDRD2DRD4DRD3KDM4E
SCHEMBL533560 0.81 NOTUM (0.58) NOTUMDRD2DRD4DRD3KDM4E
SCHEMBL272854 0.81 NOTUM (0.58) NOTUMDRD2DRD4DRD3KDM4E
SCHEMBL26785659 0.81 NOTUM (0.58) NOTUMDRD2DRD4DRD3KDM4E
SCHEMBL45348 0.81 NOTUM (0.58) NOTUMDRD2DRD4DRD3KDM4E
SCHEMBL3118178 0.81 NOTUM (0.58) NOTUMDRD2DRD4DRD3KDM4E
SCHEMBL6879933 0.81 NOTUM (0.58) NOTUMDRD2DRD4DRD3KDM4E
SCHEMBL22964275 0.81 NOTUM (0.58) NOTUMDRD2DRD4DRD3KDM4E
SCHEMBL179123 0.81 NOTUM (0.58) NOTUMDRD2DRD4DRD3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117003705-A Novel 1,2, 3-triazole compound with anti-tumor effect, and preparation method and application thereof 北京中医药大学 2023-11-07 CN claimed
CN-116947791-A Furanamide antitumor compound and preparation method and application thereof 北京中医药大学 2023-10-27 CN claimed
US-20260092052-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2026-04-02 US disclosed
CN-121591700-A Synthesis method of isopropyl omega-nimidab 沈阳药科大学 2026-03-03 CN disclosed
US-12378256-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-08-05 US disclosed
CN-116947791-B Furanamide antitumor compound and preparation method and application thereof 北京中医药大学 2025-04-25 CN disclosed
US-12162864-B2 Condensed-cyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-12-10 US disclosed
US-12065433-B2 Positive allosteric modulators of the muscarinic acetylcholine receptor M1 VANDERBILT UNIVERSITY (US) 2024-08-20 US disclosed
US-12030871-B2 Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors ORION CORPORATION (FI) 2024-07-09 US disclosed
US-12024505-B2 Heterocyclic compounds useful as modulators of acetylcholine receptors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-07-02 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-9518042-B2 Nitrogen-containing heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-13 US disclosed
US-9499516-B2 Nitrogen-containing heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-11-22 US disclosed
US-20160152598-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-06-02 US disclosed
US-20160152603-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-06-02 US disclosed
US-9315458-B2 Nitrogen-containing heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2016-04-19 US disclosed
US-20150307451-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-29 US disclosed
WO-2015163485-A1 ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-29 WO disclosed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
US-20100137250-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152598-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CHRM1, CHRM5, CHRM2 NOTUM 1245/4885DRD2 126/4885DRD4 186/4885
US-12065433-B2 Positive allosteric modulators of the muscarinic acetylcholine receptor M1 CHRM1, CHRM2, CHRM4 NOTUM 2635/4885DRD2 263/4885DRD4 579/4885
US-20160152603-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CHRM1, CHRM5, CHRM2 NOTUM 1245/4885DRD2 126/4885DRD4 186/4885
US-20260092052-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CHRM1, CHRM2, CHRM4 NOTUM 928/4885DRD2 145/4885DRD4 222/4885
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP NOTUM 476/4885DRD2 2955/4885DRD4 2976/4885
US-20100137250-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 NOTUM 2406/4885DRD2 1091/4885DRD4 2595/4885
US-12378256-B2 Heterocyclic compound SLC10A2, ALPI, VIP NOTUM 1546/4885DRD2 726/4885DRD4 1011/4885
US-12024505-B2 Heterocyclic compounds useful as modulators of acetylcholine receptors CHRM3, CHRNA1, CHRM5 NOTUM 1325/4885DRD2 299/4885DRD4 728/4885
US-12030871-B2 Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors CYP11B1, CYP11B2, CYP4A11 NOTUM 2244/4885DRD2 1694/4885DRD4 1133/4885
US-12162864-B2 Condensed-cyclic compound SLC10A2, VIP, AVPR2 NOTUM 2299/4885DRD2 1256/4885DRD4 1260/4885
US-20150307451-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CHRM1, CHRM5, CHRM2 NOTUM 1245/4885DRD2 126/4885DRD4 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.